All News

When I started receiving treatment for follicular lymphoma, I wasn’t sure what to expect regarding treatment — and a lot of things were unexpected.

Author and kidney cancer survivor Katie Coleman explains why patients with cancer need to advocate for themselves when navigating the medical system.

The novel treatment is being evaluated for patients with previously treated transfusion-dependent lower-risk myelodysplastic syndrome.

Imfinzi was approved by the FDA for the treatment of adults with limited-stage small cell lung cancer without disease progression after chemotherapy and radiation.

The FDA has approved the first systemic therapy for patients with NSCLC or pancreatic adenocarcinoma with an NRG1 gene fusion.

An expert from the CURE® advisory board explains the likely treatability of Dave Coulier’s non-Hodgkin lymphoma.

I’ve learned to live in the present by avoiding clocks, a necessary change in my life after having breast cancer.

Partial nephrectomy showed similar overall and cancer-specific survival rates to radiofrequency ablation in patients with cT1a RCC.

Patients with locally advanced pancreatic cancer demonstrated a two-month difference in survival with tumor-treating fields versus chemotherapy.

In patients with advanced solid tumors, treatment with nemvaleukin with or without Keytruda demonstrated antitumor activity and tolerability.

When my grandmother passed away one Thanksgiving after my colon cancer diagnosis, I realized how grateful I am for her life and my own as a survivor.

Singer-songwriter Danielia Cotton, a thyroid cancer survivor and marathon runner shared how her experiences impact her art.

The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed or refractory multiple myeloma.

The primary endpoint of overall survival was missed in the SKYSCRAPER-01 study assessing tiragolumab plus Tecentriq in some patients with non-small cell lung cancer.

Current treatments for patients with relapsed or refractory chronic lymphocytic leukemia have shown better outcomes than published data, an expert said.

Reflecting on my first diagnosis of breast cancer at 36 weeks pregnant has made me feel grateful for the positive moments during that dark time.

The FDA approved several drugs throughout November for the treatment of diseases including leukemia and biliary tract cancer, in addition to a diagnostic for solid cancers.

In patients with low-grade prostate cancer, adhering to the recommended dietary guidelines may slow the risk of prostate cancer progression.

Kim Moeller, a compassionate oncology nurse, empowers patients by alleviating fear and fostering hope through empathetic listening and personalized care.

Before I underwent surgery to remove tumors on several organs, I was told it was the only way to determine what cancer I had.

The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in metastatic breast cancer.

Aerobic exercise improved self-reported cognitive function in women undergoing chemotherapy for breast cancer but had no effect on objective cognitive function.

This year for Thankgiving, I reflected on how my life has been as a breast cancer veteran and how grateful I am for the support, love and care from my family.

Researchers have found an increased frequency of severe maternal morbidity and obstetric complications among women who received a diagnosis of a hematological malignancy during pregnancy.

In the cancer world — or anywhere — the ability to give thanks in the midst of trials is an acquired skill. It must be practiced.

A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus endocrine therapy.

With stage 4 colon cancer, I still think about death, but I’ve learned how to live in the present to enjoy each day I have.

Truqap combination showed a statistically and clinically meaningful improvement in radiographic progression-free survival for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.